trending Market Intelligence /marketintelligence/en/news-insights/trending/YP6FBCbHjijaLA815wF2NQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Merck & Co. completes $2.7B acquisition of cancer therapy developer ArQule

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Merck & Co. completes $2.7B acquisition of cancer therapy developer ArQule

Merck & Co. Inc. completed its $2.7 billion acquisition of Burlington, Mass.-based precision medicine specialist ArQule Inc.

The Kenilworth, N.J.-based maker of blockbuster cancer drug Keytruda offered $20 for every ArQule share acquired. At the close of the tender offer period, 75.3% of ArQule's outstanding common stock were validly tendered, with the remaining shares canceled and converted into a right to receive $20 apiece.

ArQule — whose lead product candidate is blood cancer therapy ARQ 531 — will delist from the Nasdaq Global Select Market and operate as a wholly owned subsidiary of Merck.